STRATA Skin Sciences, Inc. · OTC:SSKN

STRATA Skin Sciences — Investor Presentation (January 2023)

22 slides from STRATA Skin Sciences's investor presentation, Jan 9, 2023

  1. Slide 1: Investor Presentation | January 2023

    Investor Presentation | January 2023

  2. Slide 2: Company Overview

    Large Market Opportunity Addressing $38B market Treatment Focus Company Overview Psoriasis, Vitiligo, Eczema and Acne A medical technology company dedicated 2 Main Product Devices to developing cutting-edge solutions for XTRAC® & TheraClear®X the in-office treatment of life-altering skin conditions.

  3. Slide 3: Addressing a $38B Market

    Addressing a $38B Market XTRAC® Eczema $11.8B2 Psoriasis TheraClear®X $20.1B1 Vitiligo Acne $1.2B3 $5.5B4 1Fortune Business Insights Market Report 2019; 2016-2018 historical, 2019 base year, 2020-2027 projected 2Market Data Forecast Analysis Report 2020; 2020 base year, 2021-2026 projected 3Fortune

  4. Slide 4: Dermatology Device Market

    $10.0 13.4% CAGR Dermatology Device Market $7.5 $8.2 Billion Market1 $ in B $5.0 $2.5 0 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 1Source: Dermatology Devices From 2016 to 2018 4

  5. Slide 5: Recent Acquisitions to Drive Top-line Growth

    Recent Acquisitions to Drive Top-line Growth January 2022 August 2021 5

  6. Slide 6: XTRAC: Overview

    XTRAC®: Overview Safe, effective treatment 150+ peer-reviewed clinical studies Psoriasis treatment is the number 1 domestic use for XTRAC® lasers Opportunities exist for expanding use for other approved indications like vitiligo and eczema Clinical Support Team focused on: • In-office training • Bes

  7. Slide 7: XTRAC: Overview - 30M Patient Opportunity

    XTRAC®: Overview Eczema 5% Vitiligo 15% 30M Patient Opportunity Indications: Psoriasis, Vitiligo + Eczema Psoriasis - 8M patients in U.S. Treatments Vitiligo - 5M patients in U.S. by Indication Eczema - 18M patients in U.S. Psoriasis 80% 7

  8. Slide 8: XTRAC: Psoriasis

    XTRAC®: Psoriasis Clinical Protocol – 6.2 treatments to PASI* 75 How it Works: • Beam of UVB light applied to the affected area • UVB light induces apoptosis of the keratinocytes and T cells in the dermis • Promotes immunosuppression Baseline After 2 tx After 4 tx • Induces alterations in cytokine p

  9. Slide 9: XTRAC: Psoriasis - Treatment Options

    XTRAC®: Psoriasis Treatment Options Addressing Psoriasis Indication Topical Non-biologic NB-UVB Biologics Steroids Systemics Approximate Costs ($) 1K-3K 3K-9K 1K-7K 1K 32K-68K Clinical Impact 92% 71% 75% 48% 50-70% Speed of Onset (in Weeks) 5 10 3 14 12 Days of Actual Care 18 80 294 52 12-65 Continu

  10. Slide 10: XTRAC: Vitiligo

    XTRAC®: Vitiligo Vitiligo is an autoimmune condition due to a loss of melanocytes, characterized by patches of skin losing its pigment How it Works: • Beam of UVB light applied to the affected area • UVB light reduces the immune system's attack on the melanocytes 10 • Results in re-pigmentation • Si

  11. Slide 11: TheraClear X 50M+ Patient Opportunity

    TheraClear®X 50M+ Patient Opportunity Indications: Acne vulgaris, comedonal acne and pustular acne Dual mechanism of action (MOA) combining intense pulse light with vacuum (suction) Mechanically evacuates sebum and acne causing bacteria Addresses the estimated $5.5B acne care $5.5B market 11

  12. Slide 12: TheraClear X: Acne

    TheraClear®X: Acne TheraClear®X addresses multiple causes of acne in a single treatment How it Works: • The system combines intense pulse light with vacuum (suction) for the treatment of mild to moderate inflammatory acne, comedonal acne and pustular acne Baseline After 5 tx 12

  13. Slide 13: VTRAC Large International Opportunity

    VTRAC® Large International Opportunity Indications: Psoriasis, vitiligo and other various GD0 conditions Excimer technology with the simplicity of design and reliability of a lamp Lower-cost device 13 Marketed and sold internationally Reliable device, requires low maintenance 13

  14. Slide 14: A True Partnership

    A True Partnership Delivering a Complete Business Solution DTC Marketing Co-pay Assistance Clinical Support Field Service Support Customer Support Laser Upgrades* Reimbursement Support* Consumables and Parts *Reimbursement Support and Laser Upgrades only applies to XTRAC®. 14

  15. Slide 15: Domestic Commercial Operations

    Domestic Commercial Operations Other Statistics • Sales team targeting 7,500 dermatologists • 4 sales regions • Sales team covering 30 territories • 2 national account • Opportunity to sell TheraClear®X through existing managers salesforce • 15 field service technicians 15

  16. Slide 16: Affiliated Academic Institutions

    Affiliated Academic Institutions STRATA has placed over 50 XTRAC® machines in residency programs across academic institutions 16 16

  17. Slide 17: International Sales Operations

    International Sales Operations New experienced in-house Head of International Sales 39 international partner XTRAC® clinics Capital equipment sales preferred model Usage per device higher than in U.S. market TheraClear®X equipment sales opportunity Latin America & European markets untapped 17

  18. Slide 18: Enhancing STRATA's Business Model

    Enhancing STRATA's Business Model • Improved sales team • Improved client education + • Focused on operational performance ⚬ Transitioned sales team marketing ⚬ Improved data collection and analytics ⚬ Strengthen dermatology ⚬ KOL engagement ⚬ Messaging targeted therapy: 3 experience & relationships

  19. Slide 19: Financials

    Financials Total Revenue $33M - $35M 40,000 30,000 Est. 2022 annualized revenue, representing 20,000 strong double-digit growth 10,000 0 2018 2019 2020 2021 19

  20. Slide 20: New Management...New Focus

    New Management...New Focus 100+ Years of Sales and Operational Dermatology Experience • New leadership: CEO, CFO, VP of Marketing, VP of Professional Relations, Head of International Sales, Director of Business Operations, and 3 new board members Chief Executive Officer Chief Financial Officer VP of

  21. Slide 21: Strategic Initiatives

    Strategic Initiatives • Expansion Opportunities • Upcoming Catalysts/Milestones • Cost Savings: ⚬ Continued and growing usage of ⚬ Launch new acne device based ⚬ Net installed base growth - XTRAC® machines on acquired technology from redeploying underutilized devices ⚬ International business growth

  22. Slide 22: Company Overview

    Large Market Opportunity Addressing $38B market Treatment Focus Company Overview Psoriasis, Vitiligo, Eczema and Acne A medical technology company dedicated 2 Main Product Devices to developing cutting-edge solutions for XTRAC® & TheraClear®X the in-office treatment of life-altering skin conditions.

STRATA Skin Sciences — Investor Presentation (January 2023) on 6ix